Patent ID: 11969414
Assignee: DECIPHERA PHARMACEUTICALS, LLC
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 0:
1. A method of treating a patient suffering from an advanced gastrointestinal stromal tumor, and where the patient is being treated concurrently itraconazole, comprising
orally administering to the patient a 150 mg daily dose of ripretinib, wherein the administration of the itraconazole and the ripretinib to the patient increases ripretinib area under the plasma concentration curve (AUC0-inf) by 99% in the patient as compared to administration of ripretinib without concurrent treatment of itraconazole, and therefore the patient is at higher risk of an adverse event; and
monitoring the patient for the adverse event due to the ripretinib and itraconazole administration.